Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 once-weekly dose-finding study in adults with type 2 diabetes
2026-525465-42-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 2, randomised trial of UBT251 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to 12 weeks on a given maintenance dose. Planned start Sep 2026; status: authorised.
02
Drugs
UBT251
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2026-525465-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525465-42-00.